• Biosecure Act caveats: Market euphoria regarding US restrictions on WuXi is tempered by a six- to seven-year effective grandfathering timeline, applicability limited to federally funded projects, and Chinese firms reshoring 20% to 40% of global capacity to the US.
• Indian CDMO opportunity: New incubation business is shifting toward India through increased customer audits and signed agreements, with potential for significant growth if even 20% to 30% of displaced Chinese CDMO business migrates.
• Capacity and R&D expansion: Blue Jet plans to double its production capacity over the next two to three years while doubling its R&D talent pool and laboratory count over the next four to five months.
• Operating margin outlook: Although heavy capex may cause a near-term dip, management expects operational metrics to eventually surpass historical performance as API volumes ramp up and operating leverage takes effect.